🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Medifast stock plunges on earnings miss, weak outlook

Published 04/30/2024, 09:08 AM
Updated 04/30/2024, 09:17 AM
© Reuters.  Medifast (MED) stock plunges on earnings miss, weak outlook

Medifast (NYSE:MED), a wellness company known for its OPTAVIA brand, reported a significant decline in first-quarter revenue and earnings after the close on Monday, missing Wall Street estimates and projecting weaker-than-expected guidance for the second quarter. The company's shares plummeted 25% as investors reacted to the disappointing results and outlook.

For the first quarter ended March 31, 2024, Medifast's revenue fell to $174.7 million, a sharp 49.9% decrease from $349.0 million in the same quarter last year. This decline significantly missed the analyst consensus of $205.79 million. The company's adjusted earnings per share (EPS) for the quarter was $0.66, falling short of the expected $1.50 by analysts.

The stark revenue drop was attributed to a decrease in the number of active earning OPTAVIA Coaches, lower Coach productivity, and a $9.1 million impact from changes in the company’s sales order terms and conditions. The total number of active earning OPTAVIA Coaches decreased by 35.6% to 37,800 compared to 58,700 in the first quarter of 2023.

Despite the revenue and profit decline, the company's gross profit margin improved slightly to 72.8% from 70.6% in the prior year, benefiting from inventory management efficiencies and cost savings initiatives. However, selling, general, and administrative expenses as a percentage of revenue increased to 68.3%, up from 55.3% in the previous year, due to market research, investment costs, and company-led acquisition initiatives.

Medifast's net income also saw a steep decline to $8.3 million from $40.0 million in the first quarter of 2023. Chairman & Chief Executive Officer Dan Chard commented on the results, "While 2024 will be a year of investment for future growth, we believe the initiatives we are undertaking will be foundational in creating a platform for sustained company growth in the years ahead."

Looking ahead, Medifast forecasts second-quarter 2024 revenue to be between $150 million and $170 million, with diluted EPS ranging from $0.05 to $0.40. These figures fall below the analyst consensus, which anticipates an EPS of $0.67 and revenue of $175.1 million.

The company's balance sheet remains robust with $156.4 million in cash, cash equivalents, and investment securities, maintaining a debt-free position. Despite this, the significant earnings and revenue miss, coupled with a weak forward-looking guidance, has led to a substantial decline in Medifast's stock value, reflecting investor concerns over the company's near-term performance.

Reacting to the report, analysts at DA Davidson said Neutral-rated MED reported a small 1Q24 sales beat compared to their estimate but they noted profit missed consensus by 11% due to higher SG&A behind the new GLP-1 drug offering.

"We're cutting our 2024E EPS to $0.75 from $1.86 because: (1) while new clients may be up sequentially in 3Q24, Coaches will not (there's a lag); and (2) MED books monthly sales/drug customer of only $217 vs. ~$400 for the original 5-and-1 plan. If ad spend is $60M in 2025 rather than the $37M in our model, EPS would be $0.65 rather than our estimate of $2.25," said analysts at the firm, which also cut its target for the stock to $25 from $40.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.